Repron Therapeutics

Repron Therapeutics is a biotechnology company focused on developing innovative therapeutics to combat cancer.

Utilizing an epigenetic silencing platform, the company targets transcriptional factors of oncogenes to inhibit tumor recurrence. This approach aims to address the challenges posed by solid tumors, particularly in cases where complete removal is not feasible. The company's technology delivers Epigenetic Silencing Factors to eliminate residual tumor cells at primary sites or micrometastases in target organs. Repron's strategy is designed to tackle the complexities of cancer cell proliferation and invasiveness, providing potential solutions for difficult solid tumor cases. The team is led by Dr. Vania Broccoli, a prominent figure in cancer research.